TY - JOUR
T1 - Nutritional medicine as mainstream in psychiatry
AU - Sarris, Jerome
AU - Logan, Alan C.
AU - Akbaraly, Tasnime N.
AU - Amminger, G. Paul
AU - Balanzá-Martínez, Vicent
AU - Freeman, Marlene P.
AU - Hibbeln, Joseph
AU - Matsuoka, Yutaka
AU - Mischoulon, David
AU - Mizoue, Tetsuya
AU - Nanri, Akiko
AU - Nishi, Daisuke
AU - Ramsey, Drew
AU - Rucklidge, Julia J.
AU - Sanchez-Villegas, Almudena
AU - Scholey, Andrew
AU - Su, Kuan Pin
AU - Jacka, Felice N.
AU - on behalf of The International Society for Nutritional Psychiatry Research
N1 - Funding Information:
JS has received honoraria, research support, royalties, consultancy, or travel grant funding from Integria Health, Blackmores, Bioceuticals, Taki Mai, Pepsico, HealthEd, Soho-Flordis, Pfizer, Elsevier, the Society for Medicinal Plant and Natural Product Research, CR Roper Fellowship, and the National Health and Medical Research Council (NHMRC). ACL has received consulting fees from Genuine Health (Toronto, Canada). VB-M has received grants, and served as consultant, adviser, or continuing medical education (CME) speaker during the past 3 years for the following entities: Angelini, AstraZeneca, Bristol-Myers-Squibb, Janssen, Juste, Lilly, Lundbeck, Otsuka, the Spanish Ministry of Science and Innovation, and Fundación Alicia Koplowitz. MPF has received funding for advisory board positions, or consulting, from: Takeda, Otsuka, Lundbeck, Genentech, Johnson & Johnson, and JDS Therapeutics; pending research support from Takeda; and for medical editing for DSM Nutritionals and GOED Omega-3. YM has received research support from the Japan Science and Technology Agency, National Center of Neurology and Psychiatry (Japan), the Ministry of Health, Labour, and Welfare of Japan, and has been a paid speaker for Mochida Pharmaceutical Co, Takeda Pharmaceutical Company, Suntory Wellness, Eli Lilly Japan KK, Otsuka Pharmaceutical Co, and DHA & EPA Association. DM has received research support from the Bowman Family Foundation, FisherWallace, Nordic Naturals, Methylation Sciences, and PharmoRx Therapeutics. He has received honoraria for consulting, speaking, and writing from Pamlab, and the Massachusetts General Hospital Psychiatry Academy. He has received royalties from Lippincott Williams & Wilkins for the published book Natural medications for psychiatric disorders: considering the alternatives. TM has received research grants from the Japan Society for the Promotion of Science, the National Center for Global Health and Medicine (Japan), the National Cancer Center (Japan), the Ministry of Health, Labour, and Welfare of Japan, the Industrial Health Foundation, the Uehara Memorial Foundation, and Otsuka Pharmaceutical Co. DN has received research support from the Japan Society for the Promotion of Science and the Foundation for Total Health Promotion, and lecture fees from Qol Co, DHA & EPA Association, NTT DoCoMo, and Emotional Quotient Academy. AS has received funding from the Biotechnology and Biological Sciences Research Council (UK), The Australian Research Council, the NHMRC, the British Psychological Society, the Australian Wine Research Institute, Abbott Nutrition, Arla Foods, Bayer Healthcare, Cognis, Cyvex, GlaxoSmithKline Nutrition, Masterfoods, Martek, Naturex, Nestlé, Neurobrands, Sanofi, Verdure Sciences, and Wrigley, and received speaker fees from Abbott Nutrition, Barilla, Bayer Healthcare, Danone, Flordis, GlaxoSmithKline Healthcare, Kraft, Masterfoods, Martek, Novartis, Unilever, and Wrigley. K-PS has received research grants from the National Science Council, National Health Research Institute, and China Medical University in Taiwan, and joint research grants from the Royal Society (UK) and National Centre for Research and Development (Poland). FNJ has received grants and research support from the Brain and Behaviour Research Institute (USA), the NHMRC, Australian Rotary Health, the Geelong Medical Research Foundation, the Ian Potter Foundation, Eli Lilly, the Meat and Livestock Board Australia, and The University of Melbourne, and has been a paid speaker for Sanofi-Synthelabo, Janssen Cilag, Servier, Pfizer, Health Ed, Network Nutrition, Angelini Farmaceutica, and Eli Lilly.
Publisher Copyright:
© 2015 Elsevier Ltd.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Psychiatry is at an important juncture, with the current pharmacologically focused model having achieved modest benefits in addressing the burden of poor mental health worldwide. Although the determinants of mental health are complex, the emerging and compelling evidence for nutrition as a crucial factor in the high prevalence and incidence of mental disorders suggests that diet is as important to psychiatry as it is to cardiology, endocrinology, and gastroenterology. Evidence is steadily growing for the relation between dietary quality (and potential nutritional deficiencies) and mental health, and for the select use of nutrient-based supplements to address deficiencies, or as monotherapies or augmentation therapies. We present a viewpoint from an international collaboration of academics (members of the International Society for Nutritional Psychiatry Research), in which we provide a context and overview of the current evidence in this emerging field of research, and discuss the future direction. We advocate recognition of diet and nutrition as central determinants of both physical and mental health.
AB - Psychiatry is at an important juncture, with the current pharmacologically focused model having achieved modest benefits in addressing the burden of poor mental health worldwide. Although the determinants of mental health are complex, the emerging and compelling evidence for nutrition as a crucial factor in the high prevalence and incidence of mental disorders suggests that diet is as important to psychiatry as it is to cardiology, endocrinology, and gastroenterology. Evidence is steadily growing for the relation between dietary quality (and potential nutritional deficiencies) and mental health, and for the select use of nutrient-based supplements to address deficiencies, or as monotherapies or augmentation therapies. We present a viewpoint from an international collaboration of academics (members of the International Society for Nutritional Psychiatry Research), in which we provide a context and overview of the current evidence in this emerging field of research, and discuss the future direction. We advocate recognition of diet and nutrition as central determinants of both physical and mental health.
UR - https://www.scopus.com/pages/publications/84923302053
U2 - 10.1016/S2215-0366(14)00051-0
DO - 10.1016/S2215-0366(14)00051-0
M3 - Comment / Debate
C2 - 26359904
AN - SCOPUS:84923302053
SN - 2215-0366
VL - 2
SP - 271
EP - 274
JO - The Lancet Psychiatry
JF - The Lancet Psychiatry
IS - 3
ER -
SDG 3 Good Health and Well-being